drugset / Trial / NCT07448155

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

NCT07448155

Phase 1 Recruiting 126 enrolled Incyte Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is being conducted to evaluate the pharmacokinetics, safety, and tolerability of INCA033989 following subcutaneous (SC) or intravenous administration (IV) n healthy adult participants.

Timeline

Start
2026-03-19
Primary completion
2026-10-19
Completion
2026-10-19

Drugs

EvaluationDrugModalityDoseRoute
Subject INCA033989 Unknown Subcutaneous

Indications

No indication recorded.